Applied Therapeutics, Inc. (APLT)
NASDAQ: APLT · Real-Time Price · USD
0.4256
-0.0076 (-1.75%)
At close: Aug 8, 2025, 4:00 PM
0.4352
+0.0096 (2.26%)
After-hours: Aug 8, 2025, 7:40 PM EDT
Applied Therapeutics Stock Forecast
APLT's stock price has decreased by -93.14% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 5 analysts that cover Applied Therapeutics stock have a consensus rating of "Buy" and an average price target of $6.10, which forecasts a 1,333.27% increase in the stock price over the next year. The lowest target is $1.50 and the highest is $14.
Price Target: $6.10 (+1,333.27%)
Analyst Consensus: Buy
* Price targets were last updated on May 14, 2025.
Analyst Ratings
The average analyst rating for Applied Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Hold Reiterates $1.5 | Hold | Reiterates | $1.5 | +252.44% | May 14, 2025 |
| William Blair | William Blair | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Dec 23, 2024 |
| RBC Capital | RBC Capital | Hold Maintains $4 → $1.5 | Hold | Maintains | $4 → $1.5 | +252.44% | Dec 20, 2024 |
| UBS | UBS | Strong Buy → Hold Downgrades $13 → $2 | Strong Buy → Hold | Downgrades | $13 → $2 | +369.92% | Dec 2, 2024 |
| Citigroup | Citigroup | Strong Buy Maintains $13 → $8 | Strong Buy | Maintains | $13 → $8 | +1,779.70% | Nov 29, 2024 |
Financial Forecast
Revenue This Year
2.35M
from 455.00K
Increased by 415.60%
Revenue Next Year
33.41M
from 2.35M
Increased by 1,323.96%
EPS This Year
-0.58
from -0.76
EPS Next Year
-0.47
from -0.58
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 5.7M | 57.0M | 95.9M | ||
| Avg | 2.3M | 33.4M | 73.5M | ||
| Low | n/a | 10.2M | 51.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1,157.8% | 2,330.3% | 187.2% | ||
| Avg | 415.6% | 1,324.0% | 119.9% | ||
| Low | - | 334.4% | 54.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.48 | -0.26 | -0.27 | ||
| Avg | -0.58 | -0.47 | -0.33 | ||
| Low | -0.65 | -0.70 | -0.38 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.